EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial

Li Zhang, Mingyue Wang, Litao Zhang, Yunsheng Liang, Wenlin Yang, Liming Wu, Lei Cao, Yanyan Feng, Zudong Meng, Rixin Chen, Yingxia He, Linfeng Li und 12 weitere

British Journal of Dermatology · 2026

DOI: 10.1093/bjd/ljaf363 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Li Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatologic Agents. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: research and development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We conducted a phase IIb clinical trial of pumecitinib 3% gel (PG-011), a novel selective Janus kinase (JAK)1/2 inhibitor, applied topically to treat mild-to-moderate atopic dermatitis (AD).

Objectives

To assess pumecitinib 3% gel for its efficacy and safety in treating adult patients with mild-to-moderate AD, and to determine the optimal treatment regimen.

Methods

In this study, 139 participants with mild-to-moderate AD were randomized 1 : 1 : 1 to pumecitinib 3% gel twice daily (n = 47), pumecitinib 3% gel once daily (n = 46) and placebo (n = 46) for 8 weeks of treatment. Percentage change in Eczema Area and Severity Index (EASI) score from baseline to week 8 was the primary efficacy endpoint. The percentage of participants with an Investigator’s Global Assessment score of 0 or 1 (≥ 2-point improvement from baseline) at week 8, the proportion of participants attaining ≥ 50% improvement in EASI (EASI 50), ≥ 75% improvement in EASI (EASI 75) and ≥ 90% improvement in EASI (EASI 90) at week 8, and improvement in quality of life were also evaluated. Safety, local tolerability and some pharmacokinetics were monitored.

Results

At week 8, the percentage change from baseline in EASI score in the pumecitinib 3% gel twice daily, pumecitinib 3% gel once daily and placebo groups was –83.6%, –44.0% and –22.0%, respectively. Both pumecitinib treatment regimens showed a significantly greater effect compared with placebo (P < 0.006) and the pumecitinib 3% gel twice-daily regimen had a greater effect than once-daily treatment (P < 0.001). Other efficacy endpoints were also improved in participants in the pumecitinib groups vs. those in the placebo group, and pumecitinib 3% gel twice daily consistently exhibited better efficacy than the once-daily treatment. With regard to safety, the rate of adverse events in the pumecitinib and placebo groups was 48% and 48%, respectively. Safety profiles were generally similar between the pumecitinib and placebo groups, and treatment was well tolerated. Mean plasma drug concentrations were low (range 38–104 pg mL–1) over the 8-week treatment period.

Conclusions

Pumecitinib 3% gel showed good efficacy and safety profiles in the treatment of adults with mild-to-moderate AD. The pumecitinib 3% twice-daily treatment regimen showed greater efficacy than the once-daily regimen in treating mild-to-moderate AD. Pumecitinib 3% gel was well tolerated and generated low systemic drug exposure when used topically. It may be a new choice of topical JAK inhibitor to treat mild-to-moderate AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicDermatologic AgentsHumansFemaleMaleAdultDouble-Blind MethodTreatment OutcomeMiddle AgedGelsYoung AdultDrug Administration ScheduleAdolescentJanus Kinase InhibitorsAdministration, Cutaneous

Substanzen

GelsDermatologic AgentsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
  • Key Laboratory of Immunodermatology, Ministry of Education, and National Health Commission; National Joint Engineering Research Center for Theranostics of Immunological Skin Diseases, Shenyang, China.
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
  • Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Dermatology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, West Lake University, Hangzhou, China.

ORCID-Profile: Xinghua Gao

Förderung

  • research and development

Zitieren

APA

Zhang, L., Wang, M., Zhang, L., Liang, Y., Yang, W., Wu, L., Cao, L., Feng, Y., Meng, Z., Chen, R., He, Y., Li, L., Feng, W., Lin, B., Xu, A., Jiang, M., Xie, Z., Zhang, G., Bian, K., …, & Gao, X. (2026). Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf363

Vancouver

Zhang L, Wang M, Zhang L, Liang Y, Yang W, Wu L, et al. Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljaf363

BibTeX
@article{Zhang2026,
  author = {Zhang, Li and Wang, Mingyue and Zhang, Litao and Liang, Yunsheng and Yang, Wenlin and Wu, Liming and Cao, Lei and Feng, Yanyan and Meng, Zudong and Chen, Rixin and He, Yingxia and Li, Linfeng and Feng, Wenli and Lin, Bingjiang and Xu, Aie and Jiang, Meiying and Xie, Zhihong and Zhang, Guoqiang and Bian, Kunpeng and Ji, Chao and Yao, Weifeng and Pei, Xiaoping and Du, Daniel Y and Gao, Xinghua},
  title = {Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljaf363}
}
Kostenlos starten →